335 related articles for article (PubMed ID: 16128886)
1. A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A.
Smith MP; Giangrande P; Pollman H; Littlewood R; Kollmer C; Feingold J;
Haemophilia; 2005 Sep; 11(5):444-51. PubMed ID: 16128886
[TBL] [Abstract][Full Text] [Related]
2. Clinical safety surveillance study of the safety and efficacy of long-term home treatment with ReFacto utilizing a computer-aided diary: a Nordic multicentre study.
Petrini P; Rylander C
Haemophilia; 2009 Jan; 15(1):175-83. PubMed ID: 18752534
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety and tolerability of recombinant factor VIII (REFACTO) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria.
Pollmann H; Externest D; Ganser A; Eifrig B; Kreuz W; Lenk H; Pabinger I; Schramm W; Schwarz TF; Zimmermann R; Zavazava N; Oldenburg J; Klamroth R
Haemophilia; 2007 Mar; 13(2):131-43. PubMed ID: 17286765
[TBL] [Abstract][Full Text] [Related]
4. Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice.
Oldenburg J; Goudemand J; Valentino L; Richards M; Luu H; Kriukov A; Gajek H; Spotts G; Ewenstein B
Haemophilia; 2010 Nov; 16(6):866-77. PubMed ID: 20579113
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study.
Kim SK; Yoo KY; Lee KS; Hwang T; Choi YM; Choi EJ; Park SK
J Korean Med Sci; 2018 Jan; 33(1):e5. PubMed ID: 29215814
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting.
Musso R; Santagostino E; Faradji A; Iorio A; van der Meer J; Ingerslev J; Lambert T; Maas-Enriquez M; Gorina E;
Thromb Haemost; 2008 Jan; 99(1):52-8. PubMed ID: 18217134
[TBL] [Abstract][Full Text] [Related]
7. Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A.
Shapiro AD; Schoenig-Diesing C; Silvati-Fidell L; Wong WY; Romanov V
Haemophilia; 2015 Nov; 21(6):791-8. PubMed ID: 26010678
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.
Giangrande P; Andreeva T; Chowdary P; Ehrenforth S; Hanabusa H; Leebeek FW; Lentz SR; Nemes L; Poulsen LH; Santagostino E; You CW; Clausen WH; Jönsson PG; Oldenburg J;
Thromb Haemost; 2017 Jan; 117(2):252-261. PubMed ID: 27904904
[TBL] [Abstract][Full Text] [Related]
9. Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A.
Zhao Y; Hu Y; Jin J; Zhao X; Wang X; Wu R; Wu D; Yang R; Yang F; Hu Q; Wang J; Fang H; Engl W
Clin Appl Thromb Hemost; 2021; 27():1076029621989811. PubMed ID: 33587652
[TBL] [Abstract][Full Text] [Related]
10. Patient data meta-analysis of Post-Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF-PFM.
Iorio A; Marcucci M; Cheng J; Oldenburg J; Schoenig-Diesing C; Matovinovic E; Romanov V; Thabane L
Haemophilia; 2014 Nov; 20(6):777-83. PubMed ID: 25039809
[TBL] [Abstract][Full Text] [Related]
11. Inhibitor development, safety, and efficacy of Advate
Taki M; Fukutake K; Matsushita T; Nogami K; Shima M; Yoshioka A; Takamatsu J; Arai M; Takagi H; Uchikawa H; Engl W; Shirahata A
Int J Hematol; 2019 Jan; 109(1):70-78. PubMed ID: 30043332
[TBL] [Abstract][Full Text] [Related]
12. Pattern of bleeding in a large prospective cohort of haemophilia A patients: A three-year follow-up of the AHEAD (Advate in HaEmophilia A outcome Database) study.
Khair K; Mazzucconi MG; Parra R; Santagostino E; Tsakiris DA; Hermans C; Oldenburg J; Spotts G; Steinitz-Trost K; Gringeri A
Haemophilia; 2018 Jan; 24(1):85-96. PubMed ID: 29044825
[TBL] [Abstract][Full Text] [Related]
13. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial.
Ljung R; Kenet G; Mancuso ME; Kaleva V; Rusen L; Tseneklidou-Stoeter D; Michaels LA; Shah A; Hong W; Maas Enriquez M;
Haemophilia; 2016 May; 22(3):354-60. PubMed ID: 26663410
[TBL] [Abstract][Full Text] [Related]
14. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy.
Lentz SR; Misgav M; Ozelo M; Salek SZ; Veljkovic D; Recht M; Cerqueira M; Tiede A; Brand B; Mancuso ME; Seremetis S; Lindblom A; Martinowitz U
Haemophilia; 2013 Sep; 19(5):691-7. PubMed ID: 23647704
[TBL] [Abstract][Full Text] [Related]
15. BDDrFVIII (Moroctocog alfa [AF-CC]) for surgical haemostasis in patients with haemophilia A: results of a pivotal study.
Windyga J; Rusen L; Gruppo R; O'Brien AC; Kelly P; Roth DA; Arkin S
Haemophilia; 2010 Sep; 16(5):731-9. PubMed ID: 20412322
[TBL] [Abstract][Full Text] [Related]
16. Prophylaxis vs. on-demand treatment with Nuwiq(®) (Human-cl rhFVIII) in adults with severe haemophilia A.
Tiede A; Oldenburg J; Lissitchkov T; Knaub S; Bichler J; Manco-Johnson MJ
Haemophilia; 2016 May; 22(3):374-80. PubMed ID: 26582282
[TBL] [Abstract][Full Text] [Related]
17. Inhibitor development, safety and efficacy of Advate
Fukutake K; Taki M; Matsushita T; Nogami K; Shima M; Yoshioka A; Takamatsu J; Uchikawa H; Takagi H; Arai M; Engl W; Shirahata A
Int J Hematol; 2019 Mar; 109(3):336-345. PubMed ID: 30604312
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up.
Mauser-Bunschoten EP; Posthouwer D; Fischer K; van den Berg HM
Haemophilia; 2007 Nov; 13(6):697-700. PubMed ID: 17877729
[TBL] [Abstract][Full Text] [Related]
19. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics.
Kulkarni R; Karim FA; Glamocanin S; Janic D; Vdovin V; Ozelo M; Rageliene L; Carboni E; Laguna P; Dobaczewski G; Seremetis S; Lindblom A; Santagostino E
Haemophilia; 2013 Sep; 19(5):698-705. PubMed ID: 23651313
[TBL] [Abstract][Full Text] [Related]
20. Long-term tolerability, immunogenicity and efficacy of Nuwiq
Klukowska A; Szczepański T; Vdovin V; Knaub S; Bichler J; Jansen M; Dzhunova I; Liesner RJ
Haemophilia; 2018 Jul; 24(4):595-603. PubMed ID: 29582516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
